Synergy CHC bankruptcy opens potential Costco opportunity for Reckitt
Costco’s decision to end its 16-year Focus Factor relationship reportedly removed 58% of Synergy CHC’s 2025 revenue, while Reckitt’s Neuriva is already sold through the retailer.
Synergy CHC Corp. filed for Chapter 11 bankruptcy on 4 September 2026 after Costco ended its 16-year relationship with the Focus Factor brand, according to reporting cited by Yahoo Finance and TheStreet.
Costco reportedly accounted for approximately 58% of Synergy CHC’s net revenue in 2025. The company’s filing said the retailer’s decision was expected to have a material adverse effect on its business, liquidity and financial condition. The loss also reportedly triggered an US$18.9 million debt acceleration.
Costco has not publicly stated why it discontinued Focus Factor. The brand continues to be distributed through retailers including Walmart, Walgreens, Amazon and BJ’s, but the scale of its Costco exposure left Synergy CHC vulnerable to the loss of a single major customer.
The development could create an opportunity for Reckitt, whose Neuriva Brain Supplement Original was listed at Costco for US$43.99. Reckitt already has a supplier relationship and an established product presence with the retailer, although any increase in Neuriva orders will depend on Costco’s purchasing decisions and consumer demand.
Reckitt sells several Neuriva formulations, including Neuriva Plus, Neuriva Ultra and Neuriva Memory 3D. Its H1 2026 results showed Core Reckitt like-for-like net revenue growth of 2.7%, a 60.9% gross profit margin and £419 million in free cash flow.
Reckitt is therefore a potential beneficiary, rather than a confirmed one. The extent to which Costco reallocates shelf space or purchasing towards Neuriva remains unclear.
